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My laboratory discovered a new type of steroids. The structure of these steroids
is unique in three ways: (i) they have 23, 24 or 25 carbon atoms – no other known
vertebrate steroid has more than 21 carbon atoms; (ii) they are phosphodiesters – no
other steroid phosphodiesters are known; and (iii) some of them have a spiral
steroid at carbon 17 – no other endogenous spiral steroids are known. In total, our
laboratory had elucidated the structure and path of biosynthesis for more than 20
related compounds. We have developed an LC–MS method and a MS–MS method
to measure the compounds in small samples (< 1 ml). Synthetic compounds with
similar spiral steroids (e.g., spironolactone) function as potassium sparing hor-
mones but there were no known endogenous hormones with this function. We
propose that the natural spiral steroids have that function. Endogenous compounds
with these functions would have important roles in the physiology of pregnancy,
pre-eclampsia, and eclampsia. This chapter will review the proposed physiology and
pathology of the spiral steroids during pregnancy. There are many details to
confirm but this is a useful paradigm.
Keywords: hypertension, proteinuria, hypokalemia, edema, spiral steroids,
Ionotropin
1. Introduction
Here is a brief history of the milestones on the discovery path that led to the
discovery of phosphodiester spiral steroids and the recognition of their function as
potassium sparing hormones (KSH):
• In the 1950s, Szent-Gyorgyi proposed that digoxin was not a drug but was an
analog of a natural hormone [1].
• In the 1970s, Walsh and others developed RIAs for digoxin [2].
• In the 1980s, Graves observed that, during the third trimester, patients with
pre-eclampsia had unknown materials in their serum that cross-reacted in his
assay for digoxin [3].
• Chasalow observed that patients with Smith-Lemli-Opitz Syndrome (SLO)
were K+ wasting, had high levels of two polar steroids, of which one was a
Digoxin Like Material (DLM). By two weeks of age, both compounds were
undetectable. In normal infants there were four polar steroids, three of which
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were DLM and all four were not detectable by 2 weeks of age. We proposed
that SLO was an enzyme defect in a previously unknown pathway that
produced a compound that was potassium sparing [4].
• Bradlow observed that some human breast fluids had high K+ levels [5].
Chasalow and Bradlow speculated that the high K+ levels were caused by a
DLM the SLO patients did not make. This started a collaboration to identify the
DLM [6].
• In the 1990s, Hamlyn claimed to have isolated 13 μg of ‘ouabain’ from 80 liters
of human plasma and proposed that it was the DLM hormone anticipated by
Szent-Gyorgyi [7]. Hamlyn has not been able to confirm that the material he
isolated was present in serum samples from a patient with pre-eclampsia by
any method other than by RIA. If it were ouabain that he isolated, the
concentration in serum that he reported would have little or no consequences
[8]. The chemical properties of his material differed from the unknown DLM
we found in newborn serum and in human breast cyst fluids [6, 8].
• In the 2000s, based on the identical assay for digoxin, Chasalow isolated six
novel steroids from animal and human serum [9].
• In the 2010s, Chasalow identified the structures of the first 6 steroids and
proposed a pathway for biosynthesis with the added atoms derived from
malonyl-CoA [10]. Three of the compounds are phosphodiester conjugates of
spiral steroids. The other 3 are potential precursors. Later, we corrected the
biosynthetic pathway [11].
• In the 2020s, we observed that as early as 22 weeks of gestational age,
precursors of spiral steroids were elevated in serum from women with pre-
eclampsia but were not elevated in serum from normotensive women of
similar gestational age. We confirmed by MS–MS spectrometry that these were
steroid phosphodiesters, like those present in newborn serum and human
breast cyst fluids [12].
• Precursors were elevated in 11 of 19 women with pre-eclampsia and in only 1 of
20 normotensive pregnant women. No other proposed marker correlates with
more than 35% of affected women [13]. We propose that this divides patients
with pre-eclampsia syndrome into two diseases. This would be a major advance
in developing treatment protocols [14].
In summary, this chapter proposes a new paradigm to account for the symptoms
of pre-eclampsia. The paradigm also accounts for the long-term increased risk of
both cardiovascular disease and end-stage renal disease in affected women and their
offspring [15, 16].
2. Biochemistry of steroid phosphodiesters
This section describes the biochemistry of steroid phosphodiesters. I have used
Ionotropin as a key word in every paper about steroid phosphodiesters. I suggest
other investigators do likewise.
Ionotropin was the name we assigned to the steroid phosphodiester that was
present in human serum and not present in serum from infants with SLO syndrome.
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We now know that there are two compounds that fit the definition of Ionotropin –
C339 and C341. C339 and C341 are both present in human blood and were not
present in serum from an infant with SLO. This usage would be equivalent to using
glucocorticoid as a hormone type name and cortisol and corticosterone as specific
compounds.
2.1 Symbol convention
Based on the steroid fragment observed on mass spectroscopy, we assigned a
symbol with four characters in the ‘Zabc’ format [11]. The Z identifies which
phosphodiester is present in the molecule: (a) C = phosphocholine, (b)
P = phosphoethanolamine and (c) X = unknown. The ‘abc’ identifies the mass of the
steroid fragment observed in a positive ion mass spectrum. The method is not
antibody dependent. Anyone with a mass spectrometer can identify the appropriate
symbol for any steroid phosphodiester. Note that, potentially, there could be iso-
mers that share the same mass ion and phosphodiester fragment.
C339, C341, E339, and E341 were all present in bovine adrenal extracts but
neither E339 nor E341 were detectable in serum from any species that we tested.
This observation points to adrenal cortex as the site of synthesis.
2.2 Numbering convention
When only phosphodiester steroids with 23 carbon atoms were known, it did not
make much difference which carbon was designated # 22 or # 23. Both are part of
the E-ring. However, when we recognized that the added carbon atoms were
derived from acyl-CoEnzyme A, we have revised the numbering scheme to reflect
their common origin (Figure 1).
2.3 Mass spectrometric methods
Two basic methods were used. The first method used LC–MS with Atmospheric
Pressure Chemical Ionization (APCI) in the positive ion mode [9]. Voltages were
Figure 1.
Structures of representative steroid phosphodiesters. Starting in the upper left and going counter-clockwise, the
compounds are C313, C339, C351, and C381. Carbon 17 is the spiral steroid. Ring E is painted green and the
extra side-chain carbons are painted yellow. C339 is shown with the original, classical numbering scheme [17].
The revised scheme is shown for both C353 and C381. The new scheme recognizes carbon 22 as the carboxyl
carbon of the CoEnzyme A acyl group. This numbering scheme clarifies the proposed common origin of the extra
carbon atoms.
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selected to minimize fragmentation. The second method used direct injection into a
quadrupole ion trap mass spectrometer [12]. Spectra were collected both with and
without an additional fragmentation voltage. MS–MS analysis was also used to
confirm parent-fragment ion relationships.
Steroids have molecular masses in the range 270 to 400 Da. The smallest steroid
fragment from a phosphodiester has a molecular mass of 297 Da and the largest
fragment thus far identified has a mass of 413 Da.
2.4 Trial and error (T&E) determination of chemical composition
Table 1 illustrates the use of the T&E method to propose a composition for
C381. As shown on Line 7, only one composition of carbon, hydrogen, and oxygen
atoms can form a molecule with a mass of 398 Da - C25O4H34. Readers are invited to
test other molecular compositions to generate a molecule with a mass of 398 Da.
Similar T&E tables have been used for each of the steroid fragments we identified.
The observation that only one composition fits the mass may be a coincidence but it
certainly was useful. Occam’s razor suggests that the phosphodiesters are all related,
as precursors and/or metabolites. If this is not true, then there must be other, as yet
undetected, phosphodiester steroids.
Line Carbons Oxygen C + O H-maxHH H-Max H-Req m/z Delta
1 23 5 356 48 42 398 3
2 23 6 372 48 26 398 11
3 24 4 352 50 46 398 2
4 24 5 368 50 30 398 10
5 24 6 384 50 14 398 18
6 25 3 348 52 50 398 1
7 25 4 364 52 34 398 9
8 25 5 380 52 18 398 17
9 26 2 344 54 54 398 0
10 26 3 360 54 38 398 8
11 26 4 376 54 22 398 16
12 27 2 356 56 42 398 7
13 27 3 372 56 26 398 15
Line: Each line describes a trial of a possible composition.
Carbons: The number of carbon atoms in this specific trial.
Oxygen: The number of oxygen atoms in this specific trial.
C + O: The contribution of the carbon and oxygen atoms to the mass.
Hmax: Maximum number of hydrogen atoms – 2+ 2 for each carbon atom.
Hreq: Difference between m/z and “C + O”.
m/z: mass of the steroid fragment plus 17 Da- the fragment has lost an OH.
Delta: the number of delta necessary to complete a molecule. Delta is ½ the difference between Hmax and Hreq.
Delta is the number of rings and double bonds in the molecule. The basic steroid structure has four rings. Ring E
contributes 3 delta – ring, alkene, and the carboxylic acid. Thus, delta must be 7 or larger.
Conclusion: Line 7 (in bold) shows the molecular composition is C25O4H34 and delta must be 9.
Isomers for the proposed structure of C381 are not eliminated by the T&E analysis. The same analysis has been done
for each steroid fragment.
Table 1.
Trial and error (T&E) analysis of composition of C381.
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2.5 Spiral steroid biosynthesis
All of the newly discovered compounds are either phosphocholine (PC) steroid
diesters or phosphoethanolamine (PE) diesters. The presence of the choline
phosphodiester was confirmed by 31P-NMR (Figure 2) and by the presence of a
characteristic fragment at m/z = 184 Da in mass spectra. In humans, both choline
and ethanolamine may be essential nutriments. The phosphodiester could be added
to a steroid by condensation with CDP-serine and subsequent decarboxylation (see
Figure 2). Based on the phosphodiesters we have identified, the acceptor steroid
seems to be 17α-hydroxy-pregna-5,7-dienolone. Shackleton has isolated this com-
pound from patients with SLO [19] and Slominski has confirmed that enzymes exist
to convert 7-dehydrocholesterol to the same precursor [20].
The working theory is that the extra carbons are added by condensation of C313
or E313 with an acyl CoA (Figure 3). The three most common CoA acyl groups are:
(i) acetyl, (ii) propyl, and (iii) acetoacetyl. The three lead to steroids with 23, 24,
and 25 carbon atoms, respectively (Table 2). The three carboxylic acid intermedi-
ates were identified by their mass spectra. We can identify compounds which have
hydroxy groups by MS–MS fragmentation (by loss of 18 Da). However, it does not
identify which specific carbon atom had been hydroxylated.
C341 is the major spiral lactone in adult serum with lessor quantities of C337 and
C339. These compounds differ by stepwise reduction of the two alkenes in their
common C313 precursor. For cholesterol biosynthesis, the Δ7–8 bond must be
reduced first because cholesterol has a Δ5–6 alkene but not a Δ7–8 bond. The same
enzyme could be responsible for the reduction of Δ7–8 alkene to reduce C337 to
C339. A second reduction step is necessary to reduce the Δ5–6 bond. Although
testosterone is reduced to form the 5α derivative, that enzyme substrate specificity
requires a Δ4, 3-ketone. As the phosphodiester blocks the ketone at carbon-3, that
enzyme could not reduce C339. There is a reductase that generates 5β-metabolites.
It forms cholic acid for bile. Thus, an enzyme with this specificity would produce
the 5β-C341 isomer. Note that digoxin is also a 5β steroid.
The takeaway lesson from Figure 4 is that the 5β isomer would fit like a key into
a specific binding site in which the 5α isomer would not fit. The stereo-specificity of
C341 is probably significant because the major weak androgen in humans (but not
in most other species) is DHEA-S, which is a 5α-steroid. If C341 were a 5α- steroid,
then both DHEA and 5α-dihydrotestosterone could both interfere with its function
by binding at the receptor for C341, whatever it might be. Recall that spironolactone
also binds to both the androgen receptor and the KSH receptor. In fact, this cross-
Figure 2.
Biosynthesis of steroid phosphodiesters. Left panel. 31P–NMR of synthetic DHEA-phosphodiester [18] and of
C341 obtained by isolation from bovine adrenal extracts [9]. The three peaks are caused by the three cations
(H+, Na+, and K+). Right Panel. Condensation of serine-CDP with 17α-OH-pregna-5,7-dienolone [19, 20] to
form E313. We do not know the order of the two reactions – Decarboxylation and esterification. Mass
spectroscopy confirmed E313 was present in adrenal extracts [9].
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binding makes spironolactone a less desirable pharmaceutical. Chickens and turkeys
do not use DHEA as a weak androgen. This may explain why their serum has C339,
but not C341, as the major spiral lactone [21].
2.6 Tissue specificity
Question: why do we need all three classes of spiral lactones?
Answer: Tissue specificity. Pre-pubertal children only have 23-carbon lactones.
Gonad extracts and serum from pregnant women have 24-carbon lactones. Milk
and high K+ breast cysts have 25-carbon lactones. There are multiple forms of the
NaK-ATPase. We need to isolate each of the forms and evaluate their binding
constants to the different spiral steroids at the different forms of NaK-ATPase.
Question: why do need both PE and PC phosphodiesters?
Answer: Best answer at present is the PE compounds are for storage until needed.
N-methylation is ACTH dependent. Thus, as part of the stress response the epineph-
rine increases glycolysis and the spiral lactone increases heart efficiency [10]. We
suggest (without direct proof) that the same process occurs during childbirth.
2.7 Summary of biochemistry
The last discovery of a novel steroid was of aldosterone and that occurred in the
1950s. The general consensus has been that all of the steroids were already known.
Hamlyn’s claim to the discovery of endogenous ouabain has not been widely
accepted [7]. They reported isolating 13 μg from 80 liters of plasma (o.2 ng/ml).
Blaustein, one of his colleagues, has even published a paper asking, “Why is endog-
enous ouabain not more widely accepted?” [22]. Nicholls replied saying, “Ouabain,
a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease,
Figure 3.
Synthesis of phosphodiester spiral steroid lactones. Starting with E313, this figure shows the formation of the spiral
steroid lactones. There are several steps at the Blue arrow: N-methylation, Δ7–8 reduction, and condensation with
acyl-coenzyme A. The lactone ring formation occurs at the Red arrow. The order of the steps has not been positively
determined. The three boxes show how the three Acyl groups lead to the three different side chains at carbon 23.
The conversion of PE compounds to PC compounds (N-methylation) may occur at any step.
6
Preeclampsia
Symbol Alkenes Composition Other features
Steroids with 21 carbon atoms
C313*@ Δ5; Δ7 C21O3H30
C329*#@ Δ5; Δ7 C21O4H30 Hydroxy
Steroids with 23 carbon atoms (formed by condensation with Acetyl-CoA)
C337*@ Δ5; Δ7; Δ20 C23O3H30 !
C339*@ Δ5; Δ20 C23O3H32 ! Ionotropin
C341*@ Δ20; 5β C23O3H34 ! Ionotropin
C361*@+ Δ5 C23O4H36 22 - carboxyl
C363*@+ 5β reduced C23O4H38 22 - carboxyl
Steroids with 24 carbon atoms (formed by condensation with Propyl-CoA)
C353 Δ5, Δ20, 23-CH3 C24O3H34 !
C369#@ Δ5, Δ20, 23-CH3 C24O4H34 ! hydroxy
C371#@ 5β, Δ20, 23-CH3 C24O4H36 ! hydroxy
C389@+ Δ5, 23-CH3 C24O5H36 22 - carboxyl
Steroids with 25 carbon atoms (formed by condensation with Acetoacetyl-CoA)
C381¶ Δ5, Δ20, 23-CO-CH3 C25O4H34 !
C413#& Δ5, Δ20, 23-CO-CH3 C25O6H34 ! di-hydroxy
*Compounds purified to near homogeneity.
@ Mass spectrum also identified phosphoethanolamine (Exxx).
! Spiral steroid lactone.
# Site of hydroxy unconfirmed. Likely possible sites are at carbons 11 & 16. Compounds with an extra hydroxy
fragment by loss of water (18 Da). This eliminates hydroxy groups at the axial carbons 18, 19, and 21.
+Carboxyl compounds must be protonated in the positive ion spectrum.
¶ This fragment was detected in milk extracts from cows, sheep and goats.
& This fragment was only detected in fetal calf serum extracts.
Table 2.
Steroid phosphodiesters identified by Mass Spectroscopy.
Figure 4.
3D images of C341, a spiral steroid. Color code: carbon – grey; oxygen - red; phosphorus – orange; nitrogen –
blue. Hydrogen atoms are not shown in these images. From bottom to the top, the ring designations are A, B, C,
D, & E. Panel A and B show two different views of the 5β stereoisomer of C341. Ring A and Ring E, the spiral
ring, are both perpendicular to the plane generated by Rings B, C and D. Panel C shows the 5α stereoisomer.
Note that in the 5α stereoisomer, Ring A, B, C, and D are co-planar and only the plane of Ring E is
perpendicular to the plane of the four rings. In both stereoisomers, the PC fragment has free rotation around the
steroid plane.
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fact or fantasy?” [23]. Nicholls described two criteria required for an endogenous
hormone: [a] biosynthetic pathway and [b] a method of assay not dependent on
antibody specificity. Endogenous ouabain satisfies neither criteria. In fact, Baecher
developed an ultrasensitive LC–MS method to measure serum levels of “endoge-
nous ouabain” down to less than 2 pg./ml and could find none [24]. This section
describes both a biosynthetic path to the spiral steroids and methods to measure
spiral lactones by mass spectroscopy. It is unclear what Hamlyn measured but it is
time to consider the role of the spiral lactones as the real endogenous KSH.
3. Physiology of spiral steroid phosphodiesters
This section describes our knowledge of the function of spiral steroids. As spiral
steroid phosphodiesters are also present in oysters, the function is not limited to
mammals but is probably common throughout the animal kingdom [25]. Plants
seem to use cardiotonic glycosides for the same function. Amphibians use
marinobufagenin and related compounds as poisons to discourage predators [26].
We have not measured spiral steroids in amphibian serum to identify which spiral
steroid is used in their internal physiology. Note that marinobufagenin can only be
obtained from amphibian skin after extensive hydrolysis. As such, it would not be
expected to be present in serum.
3.1 Why do we need to regulate intracellular K+
For creatures living in the sea, ocean electrolytes are 460 mM Na + and
10 mM K+. This ratio closely resembles the electrolyte ratio in plasma 145 mM
Na + and 4 mM K+. In contrast, intracellular electrolytes are 10 mM Na + and
140 mM K+. Although we know about the role of mineralocorticoids to recover
needed Na+, until 2016, there were no known mechanisms to maintain intracellular
K+ levels or to recover K+ in the kidney.
Most plants and animals have high levels of both Na + and K+ in their tissues
and/or fluids. Thus, there is little need for a concentration mechanism for life forms
that have free access to environmental foodstuffs. However, in utero, fetuses only
have access to maternal serum electrolytes via the placenta. The fetus must con-
centrate K+ about 20-fold and must maintain the intracellular levels, despite passive
diffusion of K+ from a high K+ intracellular fluid to a low K+ extracellular fluid.
3.2 Background to endogenous K+ sparing hormones or diuretics
None known.
3.3 Background to synthetic K+ sparing diuretics (KSD)
There are two types of chemicals classified as KSD and they function by differ-
ent mechanisms. The Steroid-type, represented by spironolactone, activates K+
transport by the NaK-ATPase. The AT type, represented by amiloride or
triamterene, interfere with passage of Na + ions through the epithelial sodium
channel (ENaC). This reduces the need to ‘pump’ Na + out of cells [27].
Steroid-type KSDs include: digoxin, ouabain, spironolactone, eplerenone,
marinobufagenin. Common features include:
• E-ring lactone with 5, 6, or 7 atoms
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• Binding to most digoxin specific antibodies
• Inhibition of NaK-ATPase in the usual assay
• Pressor activity in vivo
Spiral steroid phosphodiesters have all four features.
AT Type compounds function by interfering with Na + passage through ENaC.
This activity reduces the diffusion of Na + from high Na + extracellular fluids to low
Na + intracellular fluids. This leads to lower intracellular osmotic pressure and ‘spares’
intracellular K+. The net affect is to generate a positive inotropic response [27].
3.4 Potassium accumulation in human breast cyst fluids
Earlier, because breast cysts were suspected of being precursors for breast can-
cer, the biochemistry of the cysts was investigated [5]. Based on electrolyte compo-
sition, there were two types. Type 1 had high K+ levels (60–100 mM) and Type 2
had potassium electrolyte levels resembling normal serum (5 mM). We investi-
gated DLM levels in cyst fluid samples obtained in the normal course of patient care
[6]. DLM was only present in the Type 1, high K+, samples and the levels were 10
times the levels detected in serum from normal women or men. We proposed that
the basis for the high K+ levels was the presence of a K+ regulating hormone. Type 1
fluids were used to develop methods for extraction and chromatography. The new
methods were different from that used to isolate ‘ouabain’ or ‘digoxin’ from plasma
[7]. Doping experiments confirmed that the new method would not extract
authentic cardiotonic glycosides. However, we could not collect sufficient Type 1
cyst fluid to purify the steroid phosphodiesters. In retrospect, it seems likely that
C381 was the spiral steroid actually present in the Type 1 fluids.
4. Biochemistry and physiology of spiral steroids during pregnancy
Spiral steroids function as endogenous KSH and regulate both intracellular K+
levels and K+ recovery [27]. Regulation of K+ is particularly important during
pregnancy because the fetus receives all of its nutrition via the placenta and does
not have access to K+ rich foods (Figure 5).
4.1 Fertilization
After ova are fertilized, the cells divide and multiply. The growing cells need K+
for their intracellular fluids. We detected C369 and E369 in bovine ovarian extracts.
C369 is a spiral steroid with 24 carbon atoms and a hydroxy group at an
unidentified location (Figure 6). I propose that C369 is the spiral lactone that
functions as KSH for fertilized ova. Both C329 and C353 are present in serum from
pregnant women. C369 was present in serum from 10 out of 10 (5 males and 5
females) obligate heterozygotes for SLO [29]. At present, there is no explanation for
the presence of C369 in serum from the heterozygotes but not in other men or
women.
4.2 Maternal spiral steroids during second trimester
At 22–24 weeks of gestational age, there are five steroid phosphodiesters in
maternal serum: C313, C329, C341, C353 and C381 (Figure 7). C313 and C329 have
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Figure 5.
Schematic regulation of potassium during pregnancy. The figure shows the proposed relationship between
potassium and spiral steroids during pregnancy. Most of the processes are known, but the significance of the
steroid phosphodiesters had not been recognized [28].
Figure 6.
Biosynthesis of C369. Red Arrows: condensation with Propyl-CoEnz A; Blue Arrows: Hydroxylation at
unconfirmed carbon atom. C353 and C369 are both spiral steroids.
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21 carbon atoms. The other three are spiral steroids with 23, 24, and 25 carbon
atoms, respectively.
4.3 Aldosterone signaling changes in the 3rd trimester
During the third trimester, there is a so-called ‘aldosterone-signaling defect.’
In fact, there are actually two distinct aldosterone-signaling changes during
pregnancy and these do not resolve until 2 weeks post-natal [30].
One change reduces the activity of the ENaC. This is equivalent to an AT type
activity of KSD. This leads to Na + wasting in the fetal kidney and is a key, necessary
step in producing the electrolytes for the amniotic fluid.
The second change is equivalent to the S Type of KSD, leading to increased
activity of the NaK-ATPase pump. The increase leads to increased intracellular K+
in the fetal and maternal heart. The K-Ca- exchange mechanism increases calcium
levels in the heart and results in a calcium-dependent, increased pressor response in
both the fetal and maternal compartments.
The increased fetal pressor response is necessary because, as the fetus grows, the
arterial resistance increases due to the increased length of the arterial bed. The
increase in the maternal pressor response is needed because of the increased size of
the vascular bed in the placenta. For both processes, the biology was known but the
relationship to endogenous KSH was unknown because the existence of a KSH was
unrecognized.
Figure 7.
Steroid phosphodiesters during the second trimester. Serum samples (22–24 weeks of gestational age, n = 20
normotensive women; n = 20 women with pre-eclampsia) were obtained from Global Alliance for the
Prevention of Prematurity and Stillbirth (GAPPS). Left column: normotensive women; Right column: women
with pre-eclampsia. Top: Z-scores based on intensity of miltefosine as internal control. Bottom: Representative
mass spectra. Method of analysis: For each spectrum, the intensity of each ion was compared to the intensity of
the ion generated by miltefosine (hexadecyl-phosphocholine). The mean and standard deviations of ions from
the normotensive women were calculated and used to generate Z-scores for each of the 40 samples. The Z-scores
for each sample were graphed as a cluster [12]. Ions are identified in Table 3.
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In summary, the aldosterone signaling changes are not a defect but are normal
changes that are necessary during the second and third trimester.
4.4 Preparation for milk production
Milk is unique in that it is the only major extracellular fluid with K+ levels higher
than Na + levels – 12-17 mM of K+ vs. 5–6 mM Na+ [31]. A KSH function should be
necessary to concentrate K+ from plasma (4–6 mM) to the higher K+ levels in milk.
In fact, milks from goats, cattle and sheep all had high levels of C381, suggesting
that it is the KSH required to accumulate high levels of K+. This observation
suggests that the NaK-ATPase isoform in breast tissue may be specific for C381,
rather than for any other spiral lactone.
4.5 Post-natal
Post-natal, infants are fed milk, which is high in K+, and the need for a KSH ends
but serum levels of spiral steroids remain detectable for about two weeks. Infants
remain Na + wasting and usually lose about 10% of their birth weight. By two weeks
of age, the need for KSH is over; the spiral steroids have been metabolized; aldoste-
rone function is restored; Na + wasting ends; growth resumes [30]. Mother and
infant “live happily ever after.”
4.6 Summary of the role of spiral steroids during pregnancy
Spiral steroids, acting as KSHs, play a key role in K+ regulation during preg-
nancy. Ionotropin with 23 carbon atoms is the primary KSH for maternal function.
The 24 carbon atom compounds, C353 and C369, function in the gonads and in the
fetal-placental compartment. As the mother prepares for milk production, C381, the
spiral steroid with 25 carbon atoms, directs the accumulation of K+. Ionotropin
(C339 and/or C341) and C381 are DLM. C353 and C369 have the same spiral lactone
epitope and are probably DLM, but we have not confirmed that suggestion by
isolation and testing of extracts. All of these compounds are phosphocholine steroid
diesters. The corresponding phosphoethanolamine steroid diesters are present in
extracts from tissues that ordinarily synthesize steroid hormones but are only
present in trace amounts (if at all) in serum [9].
m/z (Da) Symbol Color # of C Origin of ion Comment
353* C353 Black 24 Fragment Spiral steroid
381* C381 Green 25 Fragment Spiral steroid
475! C329 Blue 21 Loss of TMA Precursor
518 C313 Red 21 Na + ion Precursor
546 C341 Black 23 Na + ion Spiral steroid
The identify of each steroid ion was confirmed by MS–MS analysis. All parent ions were Na + ions. C313 is the
precursor for C341; C329 is the precursor for C369. One of the precursors was elevated in 11 of 19 samples from women
with pre-eclampsia.
* The ion detected is the steroid fragment after loss of the phosphocholine.
! The ion detected is derived from Na + ion after loss of trimethylamine (TMA).
Table 3.
Identification of phosphodiester steroids in serum (Figure 7).
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5. Physiology of spiral steroids in pre-eclampsia
Pre-eclampsia is a syndrome, not a disease [32]. As a syndrome, the diagnosis is
made by hypertension and proteinuria. The symptoms can begin as early as
20 weeks of gestation [33–35]. For many patients with pre-eclampsia, there is little
consequence during pregnancy. Monitoring and bed rest are often recommended.
However, about 6–10% of affected women develop life-threatening hypertension
and/or seizures. The only treatment is immediate C-section [15]. After C-section,
the seizures and hypertension usually resolve.
In addition to the classical symptoms, during the third trimester, many affected
patients also develop hypokalemia [36, 37]. In fact, there is a statistically significant
(P < o.o5) inverse relationship between maternal serum K+ levels and maternal
blood pressure [35]. Publications from 3rd world countries describe hypokalemia in
patients with pre-eclampsia but publications from 1st world countries do not
recognize hypokalemia as a symptom or risk factor.
There are several things to note in Figure 7.
• At 22–24 weeks of gestation, serum DLM is undetectable by most assays [38].
• Although C353 (an ion at m/z = 353 Da) and C341 (an ion at m/z = 546 Da)
were detected by mass spectroscopy, both ions were of low intensity and might
not be detected in a DLM assay. The variability of the intensities for these two
ions did not correlate with disease status.
• Neither C381 (detected at m/z = 381 Da) nor C329 (detected at m/z = 475 Da)
were detected in outdated human plasma [9].
• For both C313 (detected at m/z = 518 Da and C329 (detected at m/
z = 475 Da) there was a significant increase (P < 0.05) in mean serum
levels6in women with pre-eclampsia and many samples had Z-scores greater
than 2.0.
We used three different statistical methods to evaluate the ion intensity of the
C313, precursor of Ionotropin. First, we compared the mean and standard deviation
of the of the samples from the normotensive women with the corresponding data
from the women with pre-eclampsia. Second, we used Rank sum analysis. This
method does not assume a normal distribution and is considered more robust than
methods that imply a normal distribution. Third, we used the mean and standard
deviation of the normotensive women to show Z-scores for all 40 samples. This set
of data is presented in the clusters in Figure 7. There were 12 samples from the
women with pre-eclampsia with Z-scores over 2 for either C313 or C329; there was
only one sample from a normotensive woman with Z-score over 2. This distribution
is statistically significant at the P < 0.01 level. With all three methods, the differ-
ences are statistically significant at the P < o.o5 level. Although there was an
increase in the concentration of precursors, DLM was undetectable at this stage of
gestation [39].
This data portends converting pre-eclampsia from a syndrome to at least
two diseases. One disease, Type A, characterized by elevated levels of at least one of
the spiral steroid precursors (either C313 or C329), a second disease, Type B,
characterized by normal levels of the precursors. The takeaway lesson from this
study is hypertension and proteinuria seem to be symptoms of more than one
disease [40].
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5.1 Proposed biopathology of pre-eclampsia
• Inadequate implantation leads to inadequate fetal K+.
• To compensate, the placenta secretes excess spiral steroid precursors – either
C313 or C329.
• Mother responds by converting the spiral steroids to C341 or C369.
• C369 acts as a KSH in the fetal-placental unit, which further depletesmaternal K+.
• Fetal hypokalemia prevents normal growth. This may be the process that leads
to low birthweight infants.
• Hyperspirolemia (high serum levels of C341 or other spiral steroid
phosphodiester) functions as an KSH and leads to maternal hypertension and
proteinuria. Hyperspirolemia would be detected as a DLM.
• Continuous hyperspirolemia would lead to life-threatening seizures.
• Sustained hyperspirolemia damages heart and kidney and increases life-long
disease risk (Figure 8).
The initial underlying biopathology seems to be inadequate placental implanta-
tion [41, 42]. Investigators have measured many, many hormones as possible risk
factor or mediators, but none predict more than 35% of the patients who develop
the symptoms, none predict hypokalemia, none predict risk of life-threatening
hypertension [43–45], and none provide a biochemical basis for the increased life-
long risk of renal or cardiac disease.
5.2 Significance of changes in aldosterone signaling
If fetal K+ levels were inadequate, the placenta should synthesize spiral steroid
precursors, C313 and C329 [12]. This leads to their increase in the maternal circula-
tion. In turn, these compounds are converted to spiral steroids which function as
KSHs. Elevated KSH has been documented in patients with pre-eclampsia as
increased DLM levels. This seems to be a normal third trimester process occurring
during the second trimester. The preeclampsia symptoms would be caused by
interference in function of the ENaC in the kidney and by increased pressor activity
in the heart due to the secondary increase in Ca++.
Figure 8.
Changes in spiral steroids during pre-eclampsia. This figure integrates the regulatory process with the normal
role of spiral steroids acting as KSH. The biology has been known. The underlying biochemistry was unknown
prior to the discovery of the spiral steroids. The shuttling back and forth of steroid phosphodiesters between the
mother and the fetal-placenta unit is similar to the synthesis and function of estriol.
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5.3 Pilot study results
C313, the precursor for C341, was detected in serum from pregnant women by
the ion at m/z = 518 Da (generated by {a} 313 Da from the steroid fragment,
{b} + 183 Da from the PC fragment, {c} + 23 Da from the Na+, and {d} -1 Da from
the loss of the H+ = 518 Da.). 7 of 20 women diagnosed with preeclampsia had
elevated levels (Z > 2) of C313 in serum collected at 22–24 weeks of gestation. Just
like overdose of KSDs, elevated levels of C341 in maternal serum would be expected
to lead to maternal hypertension, proteinuria and hypokalemia.
C329, the precursor for C369, was detected in serum from pregnant women by
the ion at m/z = 475 Da. This ion is generated by loss of trimethyl amine (59 Da)
from the Na + ion at m/z = 534 Da. 4 of 20 women diagnosed with preeclampsia had
elevated levels (Z > 2) of C329. There was a statistically significant increase in
concentration of C329 in the affected patients when compared to the normotensive
control group. This would be expected to lead to increased levels of a KSD in the
fetal circulation without corresponding increases in the maternal circulation. How-
ever, the incidence of samples with Z > 2 for C329 did not reach statistical signifi-
cance; a larger sample size will be needed.
C329 is the precursor of C369. C369 was not detected in pre-pubertal children
but was present in 10 of 10 obligate heterozygotes for SLO. There is no report of
increased incidence of maternal hypertension or proteinuria in this group. Three of
the 40 samples had high levels of C369, presumably associated with heterozygote
carrier status for SLO.
A third group, 9 of 20 women with preeclampsia, had normal levels of both C313
and C329 at 22–24 weeks of gestation. There may be three different patterns: [a] high
levels of C313 leading to maternal hypokalemia and life-threatening hypertension, [b]
high levels of C329 leading to self-treatment of the fetal hypokalemia without gener-
ating maternal life-threatening hypertension, and [c] a 3rd group of patients with an
unrelated origin of their symptoms. Overall, only about 5–10% of women with pre-
eclampsia develop seizures and/or life-threatening hypertension later in pregnancy.
The existence of 3 diseases sharing symptoms of proteinuria and hypertension might
be the explanation for the lack of progress in developing therapy for these syndromes.
5.4 Post-partum
The green bars and peaks in Figure 7 show the C381 levels in serum from
pregnant women. At 22–24 weeks of gestation, only one of the 40 samples had
elevated levels of C381, characterized by a score of Z > 2. There was no significant
difference between the serum levels of C381 of normotensive pregnant women when
compared to the serum levels of C381 from women with pre-eclampsia. C381 could
stimulate milk production without affecting maternal heart or kidney function.
If during gestation, the mother had pre-eclampsia, long-term damage may have
occurred due to persistent hyperspirolemia. Animal models treated with plant-derived
cardiotonic steroids develop long-term heart and kidney consequences [46, 47].
6. Therapy for pre-eclampsia
6.1 Failed therapies
6.1.1 Phosphodiesterase inhibitors
One hypotheses is pre-eclampsia can be treated with phosphodiesterase inhibi-
tors, including sildenafil citrate [48, 49]. However, Podymow writes, “As currently
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understood, the hypertension of preeclampsia is secondary to placental under per-
fusion, thus lowering systemic BP is not believed to reverse the primary pathogenic
process.” [50].
6.1.2 Digibind
Digibind is an FAB isolated from an antibody to digoxin and is used to treat
patients with hypertension caused by digoxin toxicity [51]. As there are elevated
levels of DLM in serum from women with pre-eclampsia, Digibind has been tested
to determine if it would reduce hypertension in women with preeclampsia [51].
Infusion with Digibind does lead to a prompt decrease in blood pressure in affected
women. However, the effect is short lived. Within 12 hours, blood pressure has
returned to pre-therapeutic levels. The interpretation was that ane unknown agent
was bound to the FAB and excreted. However, additional amounts were synthe-
sized, leading to continued hypertension. The effort, if any, to confirm the identity
of the unknown agent has not been published.
6.1.3 Monoclonal antibodies to Marinobufagenin
Marinobufagenin is a poison originally isolated from toad skin extracts [52]. Abi-
Ghanem, with polyclonal antibodies, developed a chemifluorescent immunoassay
[53]. Agunanne used the assay to confirm elevated marinbufagenin levels in women
with preeclampsia [54]. Fedorova developed monoclonal antibodies and observed
there was an unknown factor in serum of Dahl rats that was detected by their
monoclonal antibody [55]. In the first publication, it was characterized as
marinobufagenin-like, then as endogenous marinobufagenin [56]; most recently,
just as marinobufagenin [52]. However, there are no publications describing char-
acterization of marinobufagenin, or any plausible precursor or metabolite, from any
mammalian source, other than by immunoassay.
Despite not knowing the true identity of the ‘factor’ detected by these anti-
bodies, investigators have proposed a role for marinobufagenin in pre-eclampsia in
women [57]. I do not doubt that there is at least one unknown substance that cross-
reacts with marinobufagenin-specific antibodies in serum from patients with pre-
eclampsia. I doubt that it is marinobufagenin.
6.2 Proposed therapy
The Pilot Study showed increased levels of one of the spiral steroid precursors,
C313 or C329, in the maternal circulation. The corresponding spiral steroids are
C341 and C369. High levels of C369 were present in obligate heterozygotes with
SLO but these women do not have pre-eclampsia [29]. Thus, the cause of hyper-
tension and proteinuria would seem to be C341. This leads to two significant
therapeutic suggestions: [1] monitor disease progression with C313 and [2] treat
with C369 or its precursor, C329. The goal would be to stimulate KSH activity in the
fetus without stimulating the function of a KSH in the maternal circulation.
6.3 Proposed diagnostic method
The pilot study was designed to maximize the chance of a clear positive
response. In fact, statistically that was achieved. However, it is likely that the
elevated level of C313 did not appear suddenly at 22 weeks of gestation. A large
study is needed to determine when the elevated precursor levels begin and, later in
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gestation, which spiral steroids are elevated in the patients who develop eclampsia
or HELPP syndrome [15].
7. Conclusion
One general theme in endocrinology is, “One disease to a customer.” If all
symptoms experienced by a patient are not explained by the proposed biochemis-
try, the patient has a syndrome, not a disease. This chapter title tells the story, “It’s
all about potassium.” None of the reviews that I found recognize the significance of
hypokalemia as part of the disease.
In detail, several facts stand out: [a] there is little evidence that pre-eclampsia is
a single disease, [b] the common characterization of pre-eclampsia as a syndrome
does not include hypokalemia, [c] without considering the role of spiral steroids,
there is no recognized mechanism that shows how inadequate placental implanta-
tion leads to all of the classical symptoms of pre-eclampsia, hypokalemia or to the
long-term increased risk of coronary or renal disease.
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